Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Aurobindo Pharma stock price, quote, forecast and news

AUROPHARMA.NS
INE406A01037

Price

1,496.35
Today +/-
-0.34
Today %
-2.10 %
P

Aurobindo Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Aurobindo Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Aurobindo Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Aurobindo Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Aurobindo Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Aurobindo Pharma Stock Price History

DateAurobindo Pharma Price
9/20/20241,496.35 undefined
9/19/20241,528.10 undefined
9/18/20241,539.15 undefined
9/17/20241,552.45 undefined
9/16/20241,564.00 undefined
9/13/20241,567.25 undefined
9/12/20241,564.15 undefined
9/11/20241,507.40 undefined
9/10/20241,518.40 undefined
9/9/20241,518.50 undefined
9/6/20241,537.40 undefined
9/5/20241,534.50 undefined
9/4/20241,550.15 undefined
9/3/20241,549.40 undefined
9/2/20241,553.95 undefined
8/30/20241,569.40 undefined
8/29/20241,563.15 undefined
8/28/20241,563.00 undefined
8/27/20241,551.95 undefined
8/26/20241,547.85 undefined

Aurobindo Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aurobindo Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aurobindo Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aurobindo Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aurobindo Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aurobindo Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aurobindo Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aurobindo Pharma’s growth potential.

Aurobindo Pharma Revenue, EBIT and net profit per share

DateAurobindo Pharma RevenueAurobindo Pharma EBITAurobindo Pharma Net Income
2027e369.3 B undefined57.03 B undefined47.37 B undefined
2026e354.35 B undefined59.17 B undefined47.02 B undefined
2025e322.44 B undefined52.06 B undefined40.05 B undefined
2024290.02 B undefined43.85 B undefined31.73 B undefined
2023248.55 B undefined25.38 B undefined19.28 B undefined
2022234.56 B undefined33 B undefined26.48 B undefined
2021247.75 B undefined44.19 B undefined53.35 B undefined
2020230.99 B undefined39.35 B undefined28.45 B undefined
2019195.64 B undefined33.04 B undefined23.65 B undefined
2018165 B undefined32.47 B undefined24.23 B undefined
2017150.9 B undefined30.2 B undefined23.02 B undefined
2016139.55 B undefined28.01 B undefined20.25 B undefined
2015121.21 B undefined22.79 B undefined15.76 B undefined
201481 B undefined18.28 B undefined11.73 B undefined
201358.55 B undefined6.57 B undefined2.94 B undefined
201246.27 B undefined4.13 B undefined-1.24 B undefined
201143.82 B undefined8.08 B undefined5.64 B undefined
201035.75 B undefined6.89 B undefined5.63 B undefined
200930.77 B undefined4.27 B undefined1 B undefined
200824.41 B undefined2.52 B undefined2.39 B undefined
200721.23 B undefined2.03 B undefined2.01 B undefined
200615.94 B undefined1.05 B undefined697 M undefined
200513.22 B undefined631 M undefined33 M undefined

Aurobindo Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
5.77.3910.4310.341315.4613.2215.9421.2324.4130.7735.7543.8246.2758.5581121.21139.55150.9165195.64230.99247.75234.56248.55290.02322.44354.35369.3
-29.6341.12-0.9425.8118.91-14.5220.5833.2114.9626.0916.1922.555.6126.5438.3349.6415.148.139.3418.5718.077.26-5.325.9716.6811.189.904.22
19.1722.1418.7919.6122.9726.6424.9325.0629.0531.1935.6340.8442.4739.0742.2450.0949.5350.0951.7354.9551.1954.0656.3952.8750.4152.90---
1.091.641.962.032.994.123.33.996.177.6110.9614.618.6118.0824.7340.5760.0369.978.0690.67100.14124.87139.69124.02125.3153.42000
0.71.081.141.111.591.770.631.052.032.524.276.898.084.136.5718.2822.7928.0130.232.4733.0439.3544.193325.3843.8552.0659.1757.03
12.2014.5710.8810.7212.2111.444.776.619.5410.3213.8619.2618.458.9311.2222.5618.8020.0720.0119.6816.8917.0317.8414.0710.2115.1216.1516.7015.44
0.50.740.680.730.871.090.030.72.012.3915.635.64-1.242.9411.7315.7620.2523.0224.2323.6528.4553.3526.4819.2831.7340.0547.0247.37
-47.89-7.357.2019.0425.09-96.962,012.12188.3818.66-57.95461.710.02-121.92-337.98299.0834.3528.5113.665.28-2.4120.3287.51-50.36-27.2164.6126.2217.400.75
-----------------------------
-----------------------------
375394403404454481508557664675647632640582583583584584585586586586586586585.94585.94000
-----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Aurobindo Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Aurobindo Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (B)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                   
0.150.140.050.320.50.620.592.025.832.831.250.721.860.872.061.774.6785.0612.5919.5328.3456.2145.5862.3363.26
1.151.432.013.914.354.784.535.826.266.658.99.5612.310.440.3726.3735.3746.0727.6530.834.1443.1535.0340.1246.5450.36
0.410.560.651.120.830.991.3122.722.152.332.483.4114.916.53.711.570.517.7719.7727.0915.5515.5618.7720.3425.89
0.8111.731.522.563.193.764.726.547.958.7811.0314.5515.4619.2423.683640.5643.3158.5872.467790.2775.5485.1198.08
0.01000000001.021.641.271.080.983.20.86.27.818.280.030.110.081.161.221.154.45
2.533.124.446.868.239.5910.1914.5621.3520.5922.8925.0633.2132.6441.3756.3183.8102.9492.06121.78153.32164.13198.24181.23215.46242.06
0.911.341.722.657.248.6710.5711.4912.7514.3218.3721.6922.0525.8726.3928.0731.9942.1653.261.3670.3681.1793.16106.66124.92142.85
0.020.020.240.170.0100000.6000.390.20.220.21.031.772.463.123.65.554.316.183.923.22
0000000000001.111.082.387.370.060.062.823.484.324.097.016.047.068.16
00000.170.340.540.610.420.30.460.641.41.991.631.483.354.055.6511.5122.7523.526.9131.3833.2634.81
0000.010.01000.240.540.530.530.480.510.540.550.763.894.064.068.178.339.164.294.755.965.95
0000.020.240.0600000.020.040.060.060.190.714.034.162.231.61.871.694.632.978.3213.66
0.931.361.952.837.679.0711.1112.3413.7215.7519.3822.8625.5129.7431.3638.5944.3356.2670.4389.23111.22125.15140.31157.99183.44208.66
3.464.496.399.715.918.6621.326.8935.0736.3442.2747.9258.7362.3872.7394.9128.13159.2162.49211.01264.54289.28338.54339.22398.9450.72
                                                   
185190200207233254254267267269269279291291291292292585586586586586586586585.9585.9
0.120.380.280.390.962.362.362.861.711.921.922.914.24.24.214.244.314.14.174.184.184.184.184.184.184.18
0.951.632.293.013.824.784.645.16.939.119.8315.1420.0918.5220.9531.6549.2967.9389.57111.16133.3159.47210.41234.23249.57278.48
000-0.04-0.04-0.14-0.12-0.07-0.05-0.060.39-0.04-0.130.390.611.32-0.040.26-0.610.890.844.024.136.7714.0615.18
00000000000000000000000000
1.252.22.773.574.987.247.138.158.8611.2412.4118.2924.4523.426.0637.553.8672.8793.72116.81138.91168.25219.3245.76268.4298.43
0.960.81.251.432.352.252.93.864.214.685.156.047.766.69.6413.5120.3924.5721.5523.7325.5225.7627.9527.0338.7144.54
0.010.010.010.010.010.010.010.030.020.030.0200.050.110.120.120.090.050.521.111.320.90.91.632.083.46
0.130.070.110.191.220.390.290.310.410.450.420.90.971.131.683.679.4910.812.1618.6425.4930.4528.7728.4730.6931.39
00000000.060.070.10.120.1412.3516.0822.3623.5524.9736.7329.0340.3165.5854.2248.0321.2441.6540.78
0000000000006.565.230.511.355.886.262.82.872.292.511.013.21.811.82
1.10.881.371.633.582.663.24.274.715.265.77.0827.6929.1534.3142.260.8178.466.0686.66120.21113.85106.6581.56114.94121.99
1.111.412.264.276.978.2310.3413.7320.7819.0623.2821.495.239.6511.4812.7913.117.431.814.511.82.644.895.689.423.87
0000.220.360.520.610.730.680.730.790.951.230.040.682.0500.240.492.352.812.925.754.113.93.57
0000000000.030.050.060.030.040.090.090.240.230.390.660.81.621.972.132.142.78
1.111.412.264.487.338.7510.9514.4621.4619.8224.1222.56.59.7312.2514.9413.367.92.77.535.427.1812.611.9215.4430.22
2.212.293.636.1210.9111.4114.1518.7226.1725.0729.8229.5834.1938.8846.5657.1474.1786.368.7594.19125.62121.03119.2593.48130.38152.21
3.464.496.399.6915.8918.6521.2926.8735.0336.3142.2347.8758.6362.2772.6294.64128.03159.18162.47210.99264.53289.28338.55339.24398.78450.64
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Aurobindo Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Aurobindo Pharma's financial health and stability.

Assets

Aurobindo Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Aurobindo Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Aurobindo Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Aurobindo Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.550.820.830.831.241.530.180.992.062.920.737.527.991.083.7415.3321.6827.4430.6132.4130.9137.4373.4433.7326.13
0.060.10.150.160.310.590.650.72111.281.491.722.012.493.133.333.924.285.586.689.6710.5511.2712.45
0000000000000000000000000
-0.51-0.92-1.18-0.24-0.08-2.51-0.14-1.88-2.9-1.37-3.64-4.26-6.61-1.69-5.41-14.03-9.58-18.12-1.63-18.22-22.54-4.53-23.32.96-18.06
-0.040.260.470.330.390.590.530.340.03-0.593-0.50.261.871.932.040.740.95-0.47-0.231.461.25-27.182.183.42
0.170.290.420.510.570.470.530.690.880.630.820.640.450.761.120.940.740.840.570.741.521.270.480.191.11
00.10.170.130.260.390.090.320.230.460.31.531.920.411.193.444.967.337.746.997.77.312.8512.587.17
0.060.250.271.091.850.21.220.160.191.961.364.263.353.262.756.4716.1614.232.7919.5516.5143.8133.5150.1323.93
-424-538-432-1,107-3,926-2,005-3,025-2,224-3,319-2,463-4,830-4,199-7,165-5,713-2,733-3,905-7,683-15,657-16,942-15,299-15,591-14,311-18,738-27,046-27,204
-0.4-0.5-0.59-1.42-3.74-1.94-2.72-2.49-5.13-1.07-4.06-3.99-5.99-5.63-2.46-8.19-13.98-14.45-17.87-19.27-29.03-15.685.99-32.12-39.78
0.020.04-0.16-0.310.180.070.3-0.26-1.821.390.770.211.180.080.27-4.28-6.31.21-0.93-3.97-13.44-1.3724.73-5.07-12.57
0000000000000000000000000
0.320.310.7812.081.112.13.877.91-1.414.360.095.0811.692.872.683.416.03-17.2812.0222.3-16.32-10.82-26.8723.65
0.090.27-0.090.120.591.4200.590.030.0200.050.0100.010.040.070.070.07000000
0.390.230.220.582.071.971.453.666.84-2.181.65-0.844.071.191.081.180.933.65-19.158.6419.19-19.47-13.65-29.6918.14
--290.00-420.00-462.00-539.00-461.00-526.00-761.00-1,012.00-625.00-2,312.00-701.00-550.00-10,161.00-1,121.00-937.00-1,016.00-1,109.00-801.00-1,189.00-1,654.00-1,394.00-480.00-185.00-1,112.00
-18-52-51-67-62-91-130-30-92-157-393-289-475-338-674-596-1,527-1,342-1,140-2,194-1,460-1,756-2,343-2,637-4,395
0.05-0.01-0.10.210.180.13-0.031.381.9-1.29-1.39-0.551.39-1.181.37-0.553.133.4-4.248.926.668.7125.83-11.682.3
-363-285-159-21-2,073-1,806-1,804-2,063-3,132-502-3,47060-3,814-2,450162,5608,480-1,45915,8444,24691929,50214,775.223,086-3,272.4
0000000000000000000000000

Aurobindo Pharma stock margins

The Aurobindo Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aurobindo Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aurobindo Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aurobindo Pharma's sales revenue. A higher gross margin percentage indicates that the Aurobindo Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aurobindo Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aurobindo Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aurobindo Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aurobindo Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aurobindo Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aurobindo Pharma Margin History

Aurobindo Pharma Gross marginAurobindo Pharma Profit marginAurobindo Pharma EBIT marginAurobindo Pharma Profit margin
2027e52.9 %15.44 %12.83 %
2026e52.9 %16.7 %13.27 %
2025e52.9 %16.15 %12.42 %
202452.9 %15.12 %10.94 %
202350.41 %10.21 %7.75 %
202252.87 %14.07 %11.29 %
202156.39 %17.84 %21.53 %
202054.06 %17.03 %12.32 %
201951.19 %16.89 %12.09 %
201854.95 %19.68 %14.69 %
201751.73 %20.01 %15.25 %
201650.09 %20.07 %14.51 %
201549.53 %18.8 %13 %
201450.09 %22.56 %14.48 %
201342.24 %11.22 %5.02 %
201239.07 %8.93 %-2.67 %
201142.47 %18.45 %12.86 %
201040.84 %19.26 %15.76 %
200935.63 %13.86 %3.26 %
200831.19 %10.32 %9.77 %
200729.05 %9.54 %9.47 %
200625.06 %6.61 %4.37 %
200524.93 %4.77 %0.25 %

Aurobindo Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Aurobindo Pharma earnings per share therefore indicates how much revenue Aurobindo Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aurobindo Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aurobindo Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aurobindo Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aurobindo Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aurobindo Pharma Revenue, EBIT and net profit per share

DateAurobindo Pharma Sales per ShareAurobindo Pharma EBIT per shareAurobindo Pharma Earnings per Share
2027e630.28 undefined0 undefined80.84 undefined
2026e604.75 undefined0 undefined80.24 undefined
2025e550.29 undefined0 undefined68.35 undefined
2024494.96 undefined74.83 undefined54.15 undefined
2023424.2 undefined43.31 undefined32.9 undefined
2022400.26 undefined56.32 undefined45.19 undefined
2021422.77 undefined75.41 undefined91.04 undefined
2020394.17 undefined67.14 undefined48.55 undefined
2019333.85 undefined56.37 undefined40.35 undefined
2018281.57 undefined55.41 undefined41.35 undefined
2017257.95 undefined51.62 undefined39.35 undefined
2016238.96 undefined47.96 undefined34.68 undefined
2015207.54 undefined39.02 undefined26.98 undefined
2014138.93 undefined31.35 undefined20.12 undefined
2013100.43 undefined11.27 undefined5.04 undefined
201279.51 undefined7.1 undefined-2.12 undefined
201168.46 undefined12.63 undefined8.8 undefined
201056.57 undefined10.9 undefined8.91 undefined
200947.56 undefined6.59 undefined1.55 undefined
200836.16 undefined3.73 undefined3.53 undefined
200731.97 undefined3.05 undefined3.03 undefined
200628.61 undefined1.89 undefined1.25 undefined
200526.02 undefined1.24 undefined0.06 undefined

Aurobindo Pharma business model

Aurobindo Pharma Ltd is a global pharmaceutical company based in India. It was founded in 1986 by P.V. Ramprasad Reddy, K. Nityananda Reddy, and Kambhampati Hari Babu. It has become one of the leading companies in the industry over the past 35 years. The company's business model is based on the production and distribution of generics, active pharmaceutical ingredients, and biosimilars. It operates in several divisions, covering a wide range of products. Aurobindo Pharma's main division is the manufacturing of generics, including both simple generics and complex products like biosimilars. The company also produces a variety of pharmaceutical ingredients used in industries such as pharmacy, cosmetics, and food. In addition, Aurobindo is involved in the production of biosimilars, which are biological drugs that have similar properties to existing biological products. These products have the potential to improve access to life-saving medications and generate significant cost savings. Aurobindo also manufactures products for the veterinary medicine industry, including antibiotics, antiparasitics, and vitamins. The company has also established a strong presence in the American market in recent years through acquisitions and offers a wide range of products. It has also expanded its presence in Europe, Asia, and Africa. In 2020, Aurobindo Pharma played a significant role in combating the COVID-19 pandemic by introducing several medications that can be used to treat the virus, such as hydroxychloroquine and azithromycin for mild to moderate cases. The company has earned a reputation as a leader in the generics and active pharmaceutical ingredient markets and aims to provide high-quality medications at affordable prices, making a positive contribution to global health improvement. Aurobindo Pharma is one of the most popular companies on Eulerpool.com.

Aurobindo Pharma SWOT Analysis

Strengths

1. Strong market position: Aurobindo Pharma Ltd has achieved a solid market position in the pharmaceutical industry.

2. Diversified product portfolio: The company offers a wide range of products in various therapeutic segments, which helps reduce dependence on a single product category.

3. Robust manufacturing capabilities: Aurobindo Pharma has established efficient manufacturing facilities, allowing for cost-effective production and timely delivery of products.

4. Extensive global presence: The company has a widespread international footprint, operating across multiple geographies, which helps in revenue diversification and potential growth opportunities.

Weaknesses

1. Quality control challenges: Aurobindo Pharma has faced certain quality control issues in the past, which have impacted its brand reputation and may lead to regulatory scrutiny.

2. Overdependence on few key markets: The company heavily relies on a small number of markets for a significant portion of its revenue, making it vulnerable to market-specific risks.

3. Limited pipeline of novel drugs: Aurobindo Pharma's focus has been primarily on generic drugs, lacking a substantial pipeline of breakthrough innovative medicines for future growth.

Opportunities

1. Increasing generic drug demand: The growing preference for generic medications presents an opportunity for Aurobindo Pharma to expand its market share and revenue.

2. Expansion into emerging markets: The company can explore untapped markets in developing countries, where there is a rising need for affordable healthcare solutions.

3. Strategic partnerships and acquisitions: Aurobindo Pharma can pursue collaborations or acquisitions to access new technologies, strengthen its product portfolio, or enter new markets.

Threats

1. Intense competition: The pharmaceutical industry is highly competitive, with numerous players vying for market share, which could lead to pricing pressures and reduced profitability.

2. Stringent regulatory requirements: Compliance with stringent regulations in various countries can pose challenges and increase costs for Aurobindo Pharma.

3. Intellectual property rights issues: The company may face legal disputes or delays in product launches due to patent infringement allegations or licensing complications.

Aurobindo Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Aurobindo Pharma historical P/E ratio, EBIT, and P/S ratio.

Aurobindo Pharma shares outstanding

The number of shares was Aurobindo Pharma in 2023 — This indicates how many shares 585.939 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aurobindo Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aurobindo Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aurobindo Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aurobindo Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aurobindo Pharma Stock splits

In Aurobindo Pharma's history, there have been no stock splits.

Aurobindo Pharma dividend history and estimates

In 2023, Aurobindo Pharma paid a dividend amounting to 6 INR. Dividend means that Aurobindo Pharma distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Aurobindo Pharma provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Aurobindo Pharma’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Aurobindo Pharma's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Aurobindo Pharma Dividend History

DateAurobindo Pharma Dividend
2027e1.65 undefined
2026e1.65 undefined
2025e1.64 undefined
20241.5 undefined
20236 undefined
20226 undefined
20214.5 undefined
20204.25 undefined
20192.5 undefined
20182.25 undefined
20172.75 undefined
20162.65 undefined
20152.6 undefined
20141.63 undefined
20131.38 undefined
20120.5 undefined
20110.5 undefined
20101 undefined
20090.45 undefined
20080.33 undefined
20070.25 undefined
20060.15 undefined
20050.05 undefined

Aurobindo Pharma dividend payout ratio

In 2023, Aurobindo Pharma had a payout ratio of 8.99%. The payout ratio indicates the percentage of the company's profits that Aurobindo Pharma distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Aurobindo Pharma represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Aurobindo Pharma could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Aurobindo Pharma's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Aurobindo Pharma Payout Ratio History

DateAurobindo Pharma Payout ratio
2027e9.67 %
2026e9.5 %
2025e10.44 %
20249.07 %
20238.99 %
202213.27 %
20214.94 %
20208.75 %
20196.19 %
20185.44 %
20176.99 %
20167.65 %
20159.63 %
20148.08 %
201327.28 %
2012-23.58 %
20115.68 %
201011.22 %
200929.03 %
20089.21 %
20078.25 %
200612 %
200583.33 %
Unfortunately, there are currently no price targets and forecasts available for Aurobindo Pharma.

Aurobindo Pharma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/202416.53 15.69  (-5.07 %)2025 Q1
3/31/202414.82 17.59  (18.67 %)2024 Q4
12/31/202315.79 16.04  (1.6 %)2024 Q3
9/30/202310.75 12.83  (19.34 %)2024 Q2
6/30/20239.74 9.74  (-0.01 %)2024 Q1
3/31/20239.16 8.64  (-5.67 %)2023 Q4
12/31/20229.66 8.38  (-13.29 %)2023 Q3
9/30/202210.74 6.99  (-34.94 %)2023 Q2
6/30/202210.43 8.88  (-14.88 %)2023 Q1
3/31/202210.27 12.62  (22.84 %)2022 Q4
1
2
3
4
5
...
6

Eulerpool ESG Scorecard© for the Aurobindo Pharma stock

Eulerpool World ESG Rating (EESG©)

67/ 100

🌱 Environment

60

👫 Social

79

🏛️ Governance

62

Environment

Scope 1 - Direct Emissions
447,207
Scope 2 - Indirect emissions from purchased energy
494,264
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
941,472
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
✅
Hazardous substances
✅
Fuel consumption and efficiency
✅
Water consumption and efficiency
✅

Social

Percentage of female employees12
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic❌

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies✅
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Aurobindo Pharma list of shareholders

%
Name
Stocks
Change
Date
4.40037 % HDFC Asset Management Co., Ltd.25,783,5011,404,19912/31/2023
4.32802 % Reddy (Nityananda K)25,359,572012/31/2023
33.51479 % RPR Sons Advisors Pvt. Ltd.196,376,250012/31/2023
3.80786 % Life Insurance Corporation of India22,311,726-9,501,71612/31/2023
3.49012 % Kambam (Kirthi Reddy)20,450,000012/31/2023
3.07199 % Reddy (Ramaprasad P V)18,000,000012/31/2023
2.96698 % Axis Clinicals, Ltd.17,384,716012/31/2023
2.47319 % Sivakumaran (M)14,491,360012/31/2023
2.20232 % Quant Money Managers Ltd12,904,236400,00012/31/2023
1.78480 % Mirae Asset Global Investments (India) Pvt. Ltd.10,457,832489,50112/31/2023
1
2
3
4
5
...
10

Aurobindo Pharma Executives and Management Board

Mr. M. Madan Reddy63
Aurobindo Pharma Whole-Time Director (since 2006)
Compensation 52.35 M
Mr. K. Nityananda Reddy65
Aurobindo Pharma Executive Vice Chairman of the Board, Managing Director, Promoter (since 2022)
Compensation 37.41 M
Mr. Santhanam Subramanian
Aurobindo Pharma Chief Financial Officer
Compensation 21.06 M
Mr. P. Sarath Reddy38
Aurobindo Pharma Non-Executive Director (since 2007)
Compensation 8.16 M
Mr. B. Adi Reddy
Aurobindo Pharma Compliance Officer, Company Secretary (since 2016)
Compensation 4.76 M
1
2
3

Most common questions regarding Aurobindo Pharma

What values and corporate philosophy does Aurobindo Pharma represent?

Aurobindo Pharma Ltd represents values of excellence, integrity, and innovation. The company's corporate philosophy revolves around delivering high-quality and affordable pharmaceutical products to improve global healthcare. Aurobindo Pharma is committed to maintaining the highest standards of regulatory compliance and ensuring patient safety. With a focus on research and development, the company strives to create and provide access to a diverse range of medicines across various therapeutic areas. Aurobindo Pharma's mission is to enhance the well-being and quality of life for individuals worldwide by consistently delivering superior value to its stakeholders in an ethical and sustainable manner.

In which countries and regions is Aurobindo Pharma primarily present?

Aurobindo Pharma Ltd is primarily present in various countries and regions across the globe. The company has a strong global footprint and operates in over 150 countries, including key markets such as the United States, Europe, India, and several other emerging markets. Aurobindo Pharma Ltd has established a significant presence in these regions, leveraging its robust manufacturing capabilities, research and development expertise, and a wide range of high-quality generic pharmaceutical products. The company's extensive international presence enables it to cater to a diverse customer base and contribute to improving healthcare access worldwide.

What significant milestones has the company Aurobindo Pharma achieved?

Aurobindo Pharma Ltd has accomplished several significant milestones in its journey. By adhering to high-quality standards and manufacturing innovative pharmaceutical products, the company has gained recognition worldwide. Aurobindo Pharma Ltd has achieved notable milestones such as receiving the US FDA approval for multiple abbreviated new drug applications (ANDAs), expanding its global footprint through strategic acquisitions, and consistently delivering strong financial performance. With a focus on research and development, Aurobindo Pharma Ltd continues to enhance its product portfolio and bring affordable healthcare solutions to patients across the globe.

What is the history and background of the company Aurobindo Pharma?

Aurobindo Pharma Ltd is a leading pharmaceutical company with a rich history and background. Established in 1986, the company has rapidly grown to become one of the largest vertically integrated generic pharmaceutical companies globally. Headquartered in Hyderabad, India, Aurobindo Pharma is committed to delivering high-quality, affordable medicines across various therapeutic areas. With a strong focus on research and development, the company has a diverse portfolio of over 400 products approved by regulatory authorities in more than 150 countries. Aurobindo Pharma's consistent growth and dedication to healthcare have earned it a strong reputation in the pharmaceutical industry.

Who are the main competitors of Aurobindo Pharma in the market?

Some of the main competitors of Aurobindo Pharma Ltd in the market include Teva Pharmaceutical Industries Ltd, Mylan N.V., Sun Pharmaceutical Industries Ltd, and Dr. Reddy's Laboratories Ltd.

In which industries is Aurobindo Pharma primarily active?

Aurobindo Pharma Ltd primarily operates in the pharmaceutical industry.

What is the business model of Aurobindo Pharma?

Aurobindo Pharma Ltd is a pharmaceutical company that operates under a vertically integrated business model. The company is engaged in the development, manufacturing, and marketing of generic pharmaceuticals and active pharmaceutical ingredients (APIs) globally. With a strong focus on research and development, Aurobindo Pharma strives to provide affordable and high-quality healthcare products to patients worldwide. The company's diverse product portfolio spans multiple therapeutic areas, including antiretrovirals, antibiotics, cardiovasculars, and more. Aurobindo Pharma's commitment to innovation, quality, and accessibility has catapulted it to become one of the leading players in the generic pharmaceutical industry.

What is the P/E ratio of Aurobindo Pharma 2024?

The Aurobindo Pharma P/E ratio is 27.63.

What is the P/S ratio of Aurobindo Pharma 2024?

The Aurobindo Pharma P/S ratio is 3.02.

What is the AlleAktien quality score of Aurobindo Pharma?

The AlleAktien quality score for Aurobindo Pharma is 7/10.

What is the revenue of Aurobindo Pharma 2024?

The Aurobindo Pharma revenue is 290.02 B INR.

How high is the profit of Aurobindo Pharma 2024?

The Aurobindo Pharma profit is 31.73 B INR.

What is the business model of Aurobindo Pharma

Aurobindo Pharma Ltd is a leading global pharmaceutical manufacturer with a wide portfolio of pharmaceuticals and active pharmaceutical ingredients (APIs). The company is headquartered in India and operates 18 production facilities in 7 countries worldwide to serve a variety of therapy areas such as oncology, neurology, anti-infectives, and cardiology. Aurobindo Pharma Ltd has a well-diversified business with various segments focusing on the manufacturing and marketing of pharmaceutical formulations and APIs for the domestic and international markets. The focus is on developing high-quality and cost-effective products to meet the needs of patients worldwide. One of the key segments of Aurobindo Pharma Ltd is generic manufacturing. The company produces a variety of generics for use in various therapy areas such as pain relief, diabetes, cardiovascular diseases, and infectious diseases. Additionally, the company also offers customized development services for companies in need of new formulations and APIs. Another important segment of Aurobindo Pharma Ltd is API production. The company produces a wide range of APIs used in the manufacturing of generics and finished pharmaceuticals. The focus is on manufacturing products of the highest quality at a competitive price. Aurobindo Pharma Ltd is also a leading provider of in vitro diagnostics and diabetology products. The company also offers biological products and biosimilars. Aurobindo Pharma Ltd strives to bring innovative biological drugs to the market that contribute to improving health and quality of life. The focus is on developing biosimilars that are cost-effective while meeting the highest standards of quality and safety. The company also has a presence in the field of new molecule development. Aurobindo Pharma Ltd, as well as its subsidiaries Agila Specialties and Oncobiologics, focus on the development and marketing of proprietary products that contribute to patient care improvement. In summary, Aurobindo Pharma Ltd has broad business activities, including the manufacturing and marketing of pharmaceutical formulations, APIs, and biological products. The company's focus is on offering cost-effective, high-quality products to enhance healthcare worldwide. Aurobindo Pharma Ltd is a leading provider of generics and also offers customized development and production services. The company will continue to invest in the development of new molecules to further diversify its portfolio.

What is the Aurobindo Pharma dividend?

Aurobindo Pharma pays a dividend of 6 INR distributed over payouts per year.

How often does Aurobindo Pharma pay dividends?

The dividend cannot currently be calculated for Aurobindo Pharma or the company does not pay out a dividend.

What is the Aurobindo Pharma ISIN?

The ISIN of Aurobindo Pharma is INE406A01037.

What is the Aurobindo Pharma ticker?

The ticker of Aurobindo Pharma is AUROPHARMA.NS.

How much dividend does Aurobindo Pharma pay?

Over the past 12 months, Aurobindo Pharma paid a dividend of 1.5 INR . This corresponds to a dividend yield of about 0.1 %. For the coming 12 months, Aurobindo Pharma is expected to pay a dividend of 1.64 INR.

What is the dividend yield of Aurobindo Pharma?

The current dividend yield of Aurobindo Pharma is 0.1 %.

When does Aurobindo Pharma pay dividends?

Aurobindo Pharma pays a quarterly dividend. This is distributed in the months of July, March, December, March.

How secure is the dividend of Aurobindo Pharma?

Aurobindo Pharma paid dividends every year for the past 23 years.

What is the dividend of Aurobindo Pharma?

For the upcoming 12 months, dividends amounting to 1.64 INR are expected. This corresponds to a dividend yield of 0.11 %.

In which sector is Aurobindo Pharma located?

Aurobindo Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aurobindo Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aurobindo Pharma from 3/4/2024 amounting to 1.5 INR, you needed to have the stock in your portfolio before the ex-date on 2/20/2024.

When did Aurobindo Pharma pay the last dividend?

The last dividend was paid out on 3/4/2024.

What was the dividend of Aurobindo Pharma in the year 2023?

In the year 2023, Aurobindo Pharma distributed 6 INR as dividends.

In which currency does Aurobindo Pharma pay out the dividend?

The dividends of Aurobindo Pharma are distributed in INR.

All fundamentals about Aurobindo Pharma

Our stock analysis for Aurobindo Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aurobindo Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.